Sponsor

GTx

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name GTx appears in 15 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials15
Recruiting shown0
Roles1
SourceClinicalTrials.gov
Advertisement

Clinical trials

15 shown
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body MassNCT02746328 · lead sponsor · 2016-04-01
WITHDRAWN
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast CancerNCT02463032 · lead sponsor · 2015-08-01
COMPLETED
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)NCT02368691 · lead sponsor · 2015-06-01
TERMINATED
Phase II Study of GTx024 in Women With Metastatic Breast CancerNCT01616758 · lead sponsor · 2013-04-01
TERMINATED
Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate CancerNCT01615120 · lead sponsor · 2012-08-14
COMPLETED
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate CancerNCT01420861 · lead sponsor · 2011-09-01
TERMINATED
Phase II, Dose Finding Study of GTx-758NCT01393119 · lead sponsor · 2011-08-01
TERMINATED
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line PlatinumNCT01355497 · lead sponsor · 2011-07-01
COMPLETED
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)NCT01355484 · lead sponsor · 2011-07-01
COMPLETED
Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate CancerNCT01326312 · lead sponsor · 2011-06-01
TERMINATED
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate CancerNCT01214291 · lead sponsor · 2011-03-01
WITHDRAWN
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.NCT00467844 · lead sponsor · 2007-05-01
COMPLETED
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)NCT00106691 · lead sponsor · 2005-01-01
COMPLETED
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation TherapyNCT00129142 · lead sponsor · 2003-10-01
COMPLETED
A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)NCT00028353 · lead sponsor · 2001-04-01
COMPLETED

Drugs studied in this sponsor's trials

3 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing GTx as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo4
toremifene1
toremifene citrate1
placebo RxCUI 8375 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials toremifene RxCUI 38409 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial toremifene citrate RxCUI 49953 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor15
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.